FAIRplus: new project to improve data sharing and reuse in life sciences research


On February 1st, the FAIRplus project kicked off. This project aims to improve data management and data governance in European health research by increasing the discovery, accessibility and reusability of data from selected projects funded by the EU’s Innovative Medicine Initiative (IMI), and internal data from pharmaceutical industry partners. CMAST - a leading consultancy and project management company in life sciences – is also involved in this project, in support of Janssen Pharmaceutica.

The Innovative Medicine Initiative has a total budget of €5.3 billion and has launched over 100 individual projects across all areas of pharmaceutical research and drug development. To take advantage of the wealth of life sciences data produced by these projects, these data need to be readily available to other researchers, so that they can find them and integrate them with the outcomes of their own experiments. The gold standard in data management is to make life sciences data FAIR - Findable, Accessible, Interoperable and Reusable.


The FAIRplus project will develop methodologies and tools to increase the FAIR-ness of data and demonstrate the added value of the FAIR-fication process on selected IMI projects and datasets from the European Federation of Pharmaceutical Industries and Associations (EFPIA). Even though pharma companies within the FAIRplus consortium may not be able to share their data widely, their data scientists will use the methodology and tools internally to improve their data management procedures. Trainings will be organized for data scientists in academia, SMEs and pharmaceutical companies to enable wider adoption of best practices in life sciences data management.


The project involves 22 pharmaceutical, small company and academic partners from nine European countries. It is funded by the IMI as a public-private partnership and will run for three and a half years (2019-2022). Janssen Pharmaceutica NV is the pharmaceutical industry lead of the project - with coordination provided by ELIXIR.


For more details, please visit the CMAST website.


The FAIRplus project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 802750. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA Companies. This communication reflects the views of the authors and neither IMI nor the European Union, EFPIA or any Associated Partners are liable for any use that may be made of the information contained herein.



CMAST is a leading consultancy and project management company in life sciences.

With a team of more than 90 industry experts, CMAST provides support to pharma and life sciences companies, universities and research institutes.

The company offers consultancy, project management and tangible business solutions in the following areas:

  • Early stage innovation services
  • Funding services
  • Project & Portfolio Management
  • R&D process optimization
  • Multi-stakeholder collaborations
  • Regulatory compliance & quality
  • Health data analytics & visualization
  • Supply chain

CMAST is headquartered in Temse (Belgium) and has branches in Germany, Poland and the US. Since 2018, CMAST is working together closely with XPE Pharma & Science to connect life sciences businesses and talent in a fast-changing world. CMAST and XPE Pharma & Science are both part of the Modis Group, which gives the companies a global reach. More info on https://www.c-mast.com



Interested in a regular update of the Life Sciences and biotech sector in Flanders?